Nuvalent (NUVL) Cash from Investing Activities (2021 - 2026)
Nuvalent's (NUVL) quarterly Cash from Investing Activities came in at -$19.4 million in Q1 2026, down 176.38% YoY from $25.4 million in Q1 2025, and up 93.09% on a QoQ basis from -$280.9 million in Q4 2025.
Analysis
Nuvalent (NUVL) Cash from Investing Activities (2021 - 2026) Analysis & Trends
Nuvalent (NUVL) has 6 years of Cash from Investing Activities data on file, last reported at -$19.4 million in Q1 2026.
- Quarterly Cash from Investing Activities fell 176.38% year-over-year to -$19.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$168.9 million (up 50.51% YoY) and the FY2025 annual result came in at -$124.1 million, up 78.37% from the prior year.
- Cash from Investing Activities improved to -$19.4 million in Q1 2026, from -$280.9 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $77.5 million in Q2 2025 to a low of -$280.9 million in Q4 2025.
- A 5-year average of -$51.2 million and a median of $1.6 million in 2023 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities sank 1074.65% — and 2024, when it soared 916.81%.
- Tracing NUVL's Cash from Investing Activities over 5 years: stood at -$65.4 million in 2022, then gained by 13.98% to -$56.3 million in 2023, then slumped by 202.24% to -$170.0 million in 2024, then plunged by 65.22% to -$280.9 million in 2025, then jumped by 93.09% to -$19.4 million in 2026.
- The last three Cash from Investing Activities figures came in at -$19.4 million (Q1 2026), -$280.9 million (Q4 2025), and $54.0 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Nuvalent | 9.75 Bn | 9.75 Bn | - | -19.41 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -19.41 Mn |
| Dec 31, 2025 | -280.94 Mn |
| Sep 30, 2025 | 53.97 Mn |
| Jun 30, 2025 | 77.48 Mn |
| Mar 31, 2025 | 25.42 Mn |
| Dec 31, 2024 | -170.05 Mn |
| Sep 30, 2024 | -212.91 Mn |
| Jun 30, 2024 | 16.21 Mn |
| Mar 31, 2024 | -206.77 Mn |
| Dec 31, 2023 | -56.26 Mn |
| Sep 30, 2023 | 38.40 Mn |
| Jun 30, 2023 | 1.59 Mn |
| Mar 31, 2023 | -127.26 Mn |
| Dec 31, 2022 | -65.40 Mn |
| Sep 30, 2022 | 17.57 Mn |
| Jun 30, 2022 | 24.11 Mn |
| Mar 31, 2022 | 13.06 Mn |
| Dec 31, 2021 | -163.46 Mn |
| Sep 30, 2021 | -56.57 Mn |